MondegarAI
Avidity Partners Management LP

Q4 2025 · 13F-HR

Avidity Partners Management LPholdings as filed

Filed 2026-02-13 · accession 0001791827-26-000002

$346.7M
Reported value
39
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · Avidity Partners Management LP · Q4 2025

AI · grounded in 13F

Avidity Partners Management LP closed its position in BMY, reducing exposure by $11.6M. The fund established new positions in ALNY for $8.35M, ICLR for $6.03M, and A for $5.65M. Additionally, the manager trimmed its holdings in NTRA by 83.2% and DHR by 68.9%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
252828108DNTHDIANTHUS THERAPEUTICS INC$86.7M25.0%2,104,184CommonSOLE
156944100CGONCG ONCOLOGY INC$61.1M17.6%1,472,699CommonSOLE
008064206JBIOJADE BIOSCIENCES INC$21.6M6.23%1,400,708CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$20.0M5.77%660,424CommonSOLE
881624209TEVATEVA PHARMACEUTICAL INDS LTD$13.0M3.76%417,300CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$10.9M3.15%114,500CommonSOLE
G5960L103MDTMEDTRONIC PLC$10.3M2.98%107,600CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$8.8M2.55%3,210,733CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$8.4M2.41%21,000CommonSOLE
759916109RGENREPLIGEN CORP$8.2M2.38%50,300CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$8.1M2.33%5,504,855CommonSOLE
58155Q103MCKMCKESSON CORP$7.8M2.25%9,520CommonSOLE
G4705A100ICLRICON PLC$6.0M1.74%33,100CommonSOLE
00846U101AAGILENT TECHNOLOGIES INC$5.6M1.63%41,500CommonSOLE
717081103PFEPFIZER INC$5.1M1.46%203,600CommonSOLE
15135B101CNCCENTENE CORP DEL$4.9M1.42%119,400CommonSOLE
49177J102KVUEKENVUE INC$4.0M1.16%232,800CommonSOLE
235851102DHRDANAHER CORPORATION$3.9M1.12%17,000CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$3.9M1.12%6,700CommonSOLE
670100205NVONOVO-NORDISK A S$3.4M0.99%67,300CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$3.4M0.99%206,076CommonSOLE
29261A100EHCENCOMPASS HEALTH CORP$3.4M0.97%31,600CommonSOLE
125523100CITHE CIGNA GROUP$3.2M0.92%11,600CommonSOLE
03073E105CORCENCORA INC$3.2M0.92%9,400CommonSOLE
457669307INSMINSMED INC$3.1M0.89%17,700CommonSOLE
941848103WATWATERS CORP$3.1M0.89%8,100CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$2.9M0.82%106,900CommonSOLE
372303206GMABGENMAB A/S$2.8M0.82%92,000CommonSOLE
632307104NTRANATERA INC$2.7M0.78%11,800CommonSOLE
4525EP101VTLUSDIMMUNIC INC$2.5M0.72%4,699,411CommonSOLE
00404A109ACHCACADIA HEALTHCARE COMPANY IN$2.4M0.69%169,000CommonSOLE
45826H109ITGRINTEGER HLDGS CORP$2.3M0.67%29,800CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$2.2M0.62%140,300CommonSOLE
697947109PVLAPALVELLA THERAPEUTICS INC NE$2.0M0.58%19,300CommonSOLE
42226A107HQYHEALTHEQUITY INC$1.5M0.45%16,900CommonSOLE
811292200SCYXSCYNEXIS INC$1.3M0.38%2,081,660CommonSOLE
46266C105IQVIQVIA HLDGS INC$991,8040.29%4,400CommonSOLE
48576U205KPTIKARYOPHARM THERAPEUTICS INC$990,4060.29%134,566CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$765,6000.22%22,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.